Filiz YILDIRIM, Hasan KARAGEÇİLİ, Reyhan ÖZTÜRK, Zuhal YILDIRIM

COVID-19’un progresyonu ve prognozunda Diabetes mellitus’un rolü

Amaç: Koronavirüs ailesinden SARS-CoV-2’nin neden olduğu COVID-19 pandemisi, ilk olarak Çin’de görülen ve bulaşıcılık özelliği yüksek bir hastalıktır. Hastalığın mortalite ve morbiditesinde diyabet başta olmak üzere komorbid hastalıkların varlığı ve ileri yaş belirleyici olmaktadır. Bu çalışmada Diabetes mellitus (DM)’un, yeni koronavirüs hastalığının (COVID-19) seyrindeki olası rolünün incelenmesi amaçlanmıştır. Yöntem: Bu çalışmada, 01 Ocak-05 Mayıs 2021 tarihleri arasında Ankara Polatlı Duatepe Devlet Hastanesine başvuran ve COVID-19 olduğu doğrulanan ve COVID-19 servisinde 5 ila 20 gün yatan 81 hastanın verileri incelendi. Çalışmaya 39 kadın ve 42 erkek hasta dahil edildi ve hastalar üç gruba ayrıldı. COVID-19 grubu (n=26; 10 kadın, 16 erkek), COVID-19+DM grubu (n=28; 13 kadın, 15 erkek) ve COVID-19+hipertansiyon (HT) grubu (n=27; 16 kadın, 11 erkek). Hastaların demografik, klinik, radyolojik ve laboratuvar kayıtları geriye dönük olarak incelendi. Bulgular: Gruplar arasında yaş ve cinsiyet açısından istatistiksel olarak anlamlı bir fark vardı (p

The role of Diabetes mellitus in the progression and prognosis of COVID-19

Objective: The COVID-19 pandemic, caused by SARS-CoV-2 of Coronaviruses types, is a highly infectious disease caused by SARS-CoV-2, which first appeared in China. The presence of comorbid diseases, especially diabetes, and advanced age are determinants of the mortality and morbidity of the disease. In this study, it was aimed to examine the possible role of Diabetes mellitus (DM) in the course of the novel coronavirus disease (COVID-19). Methods: In this study, the data of 81 patients who applied to Ankara Polatlı Duatepe State Hospital between January 01 and May 05, 2021 and were confirmed to have COVID-19 and were hospitalized in the COVID-19 service for 5 to 20 days were analyzed. 39 female and 42 male patients were included in the study and the patients were divided into three groups. COVID-19 group (n=26; 10 female, 16 male), COVID-19+DM group (n=28; 13 female, 15 male), and COVID-19+hypertension (HT) group (n=27; 16 female, 11 male). Demographic, clinical, radiological and laboratory records of the patients were reviewed retrospectively. Results: There was a statistically significant difference between the groups when they matched for age and gender (p

PDF

___

1. Chen N, Zhou M, Dong X, Jieming Q, Fengyun G, Yang H, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020; 395: 507-13.
2. Bai L, Yang D, Wang X, Tong L, Zhu E, Zhong N, et al. Chinese experts’ consensus on the Internet of Things-aided diagnosis and treatment of coronavirus disease 2019 (COVID-19). Clinical eHealth, 2020; 3: 7-15.
3. Ye F, Xu S, Rong Z, Xu R, Liu X, Deng P, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis, 2020; 94:133-8.
4. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine, 2020; 21: 100331.
5. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. J Infect, 2020; 80(5): e7-e13.
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020; 579(7798): 270-3.
7. Kuba K, Imai Y, Rao S, Gao H, Feng G, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005; 11: 875-9.
8. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Olubukola A, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020; 367: 1260-3.
9. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7 Axis of the renin-angiotensin system in heart failure. Circ Res, 2016; 118: 1313-26.
10. Knapp S. Diabetes and infection: is there a link? -a mini-review. Gerontology, 2013; 59: 99-104.
11. Muller LMAJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AIM, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis, 2005; 41: 281-8.
12. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology, 2015; 144: 171-85.
13. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med, 2006; 23: 623-8.
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323: 1061-9.
15. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS. Comorbidity and its impact on 1590 patients with COVID-19 in China: a Nationwide analysis. Eur Respir J, 2020; 55: 2000547.
16. Nair A, Rodrigues JCL, Hare S, Edey A, Devaraj A, Jacob J, et al. A British society of thoracic imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic. Clin Radiol, 2020;75:329-34.
17. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT severity score: An imaging tool for assessing severe COVID-19. Radiology: Cardiothoracic Imaging 2020;2:e200047.
18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; 7: 323: 1239-42.
19. Zhu N, Zhang D, Wang W, Li X, Yang B. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020; 382: 727-33.
20. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020; 382: 1708-20.
21. Shu CJ, Benoist C, Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Semin Immunol, 2012; 24: 436-42.
22. Xu M, Liu PP, Li H. Innate immune signaling and its role in metabolic and cardiovascular diseases. Physiol Rev, 2019; 99: 893-948.
23. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med, 2020; 9: E575.
24. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020; 75: 1730-41.
25. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020; 395: 1054-62.
26. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet, 2018; 6: 476-86.
27. Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ, 2019; 367: 15887.
28. Jali MV, Shankar PS. Transient diabetes following chicken pox. J Assoc Physicians India, 1990; 38: 663-4.
29. Sharif N, Ahmed SN, Opu RR, Tani MR, Dewan D, Daullah UD, et al. Prevalence and impact of diabetes and cardiovascular disease on clinical outcome among patients with COVID-19 in Bangladesh. Diabetes Metab Syndr, 2021; 15: 1009-16.
30. Harbuwono DS, Handayani DOTL, Wahyuningsih ES, Supraptowati N, Kurniawan F, Ananda, et al. Impact of diabetes mellitus on covid-19 clinical symptoms and mortality: Jakarta’s covid-19 epidemiological registry. Prim Care Diabetes, 2021; 9918: 1-4.
31. Batiha GE, Gari A, Elshony N, Shaheen HM, Abubakar MB, Adeyemi SB, et al. Hypertension and its management in COVID-19 patients: The assorted view. Int J Cardiol Cardiovasc Risk Prev, 2021; 11: 200121.
32. Martínez-Urbistondo M, Moreno-Torres V, Mora-Vargas A, Exposito-Palomo E, Castejon-Diaz R, Daimiel L, et al. Interaction of ACEI antihypertensive agent’s administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes. Vascul Pharmacol, 2022; 143: 106955.
33. An J, Zhou H, Wei R, Luong TQ, Gould MK, Mefford MT, et al. COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system. Int J Cardiol Hypertens, 2021; 9: 100088.
34. Kabootari M, Habibi Tirtashi R, Hasheminia M, Bozorgmanesh M, Khalili D, Akbari H, et al. Clinical features, risk factors and a prediction model for in-hospital mortality among diabetic patients infected with COVID-19: data from a referral centre in Iran. Public Health, 2022; 202: 84-92.
35. Albalawi O, Alharbi Y, Bakouri M, Alqahtani A, Alanazi T, Almutairi AZ, et al. Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia. J Infect Public Health, 2021; 14(8): 994-1000.
36. Cordero A, Santos García-Gallego C, Bertomeu-González V, Facila L, Rodriguez-Manero M, Escribano D, et al. Mortality associated with cardiovascular disease in patients with COVID-19. REC: Cardio Clinics, 2021;56 :30-8.
37. Eid RA, Attia AM, Hassan M, Shaker MA, Kamal MA. Demographic, clinical, and laboratory characteristics of patients with COVID-19 during the second and third waves of the pandemic in Egypt. J Infect Public Health, 2021; 14(10): 1358-66.
38. Yilmaz A, Sabirli R, Seyit M, Ozen M, Oskay A, Cakmak V, et al. Association between laboratory parameters and CT severity in patients infected with Covid-19: A retrospective, observational study. Am J Emerg Med, 2021; 42: 110-4.
39. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int, 2020; 40: 1278-81.
40. Çavuş Z, Tezdönen M, Çekme M, Türkmen ÜA. Determination of plateletcrit, mean platelet volume in patients with COVID 19 pneumonia. J Immunol Clin Microbiol, 2021; 6: 81-9.
41. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020; 36: 1-9.
42. Karageçili H, Yıldırım Z. Epidemiological and clinical aspects of the COVID-19 pandemic and world common experiences in treatment: Turkey experience. Türk Hij Den Biyol Derg, 2020; 77 (3): 355-66.
43. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol, 2020; 13: 1265-75.